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Background: Transcatheter mitral valve repair and replacement (TMVR) is a minimally invasive alterna-
tive to conventional open-heart mitral valve replacement (OMVR). The present study aims to compare
the burden, demographics, cost, and complications of TMVR and OMVR.
Methods: The United States National Inpatient Sample (US-NIS) for the year 2017 was queried to identify
all cases of TMVR and OMVR. Categorical and continuous data were analyzed using Pearson chi-square
and independent t-test analysis, respectively. An adjusted odds ratio (aOR) based on the ordinal logistic
regression (OLR) model was calculated to determine the association between outcome variables.
Results: Of 19,580 patients, 18,460 (94%) underwent OMVR and 1120 (6%) TMVR. Mean ages of patients
were 63 ± 14 years (OMVR) and 67 ± 13 years (TMVR). Both cohorts were predominantly Caucasian (73%
OMVR vs. 74.0% TMVR). The patients who underwent TMVR were more likely to belong to a household
with an income in the highest quartile (26.1% vs. 22.0% for OMVR) versus the lowest quartile (22.1%
vs. 27.8%). The average number of days from admission to TMVR was less compared to OMVR (2.63 days
vs. 3.02 days, p = 0.015). In-hospital length of stay (LOS) was significantly lower for TMVR compared to
OMVR (11.56 vs. 14.01 days, p=<0.0001). Adjusted in-hospital mortality taking into account comorbidi-
ties showed no significant difference between the two groups (OR 1.2, 0.93–1.68, p = 0.15).
Conclusion: Patients undergoing TMVR were older and more financially affluent. TMVR was more costly
but was associated with a shorter hospital stay and similar mortality to OMVR.
 2020 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
1. Introduction
Transcutaneous mitral valve repair (TMVR) has recently
emerged as an alternative to open mitral valve repair (OMVR).
[1] An edge-to-edge mitral leaflet repair device (the MitraClip) is
currently the only US Food and Drug Administration (FDA)
approved non-surgical device for mitral regurgitation. This tran-
scatheter technology involves clipping together the middle seg-
ments of the anterior and posterior mitral valve leaflets, thereby
reducing the regurgitant area by creating a ‘‘double orifice” mitral
valve [1]. The anterior and posterior mitral valve leaflets are
grasped together with a cobalt-chromium clip covered with
polypropylene fabric, thereby reducing mitral regurgitant backflow
[2].
Individuals with multiple co-morbidities and at high surgical
risks, who are not suitable candidates for OMVR, may benefit from
TMVR. TMVR is associated with lower procedural and postopera-
tive complications [1]. TMVR resulted in better preservation of
ventricular function and decreased the need for anticoagulant
use [2]. In some cases, this procedure needs to be repeated if the
regurgitant flow remains high [3]. In-hospital complications occur
in up to 13% of patients; mostly major bleeding in 7.4% patients,
and stroke and myocardial infarction in < 1% cases [3]. Earlier stud-
ies have linked TMVR with a higher mortality rate. This can be
attributed to the complex anatomy of the mitral valve; and the fact
that mitral valve replacement or repair affects cardiac function and
https://doi.org/10.1016/j.ijcha.2020.100540
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physiology, regardless of the method used to fix the mitral valve
[4]. Complications mainly occurred in older patients who were
critically ill prior to intervention [3].
Despite an increase in patients undergoing TMVR as alternative
management to OMVR, there is limited literature on this topic [5].
The present study aims to compare the burden, demographics,
cost, and complications of TMVR and OMVR.
2. Methods
2.1. Source of data
The National Inpatient Sample (NIS) database for the year 2017
was systematically searched using international classification of
diseases, 10th revision (ICD-10) coding. The NIS is the largest
accessible dataset, which contains a 20% sample of all discharges
from>4000 United States (US) hospitals [6]. The total unweighted
sample comprises 7 million nationwide discharges. Due to the
anonymous nature of data, NIS does not require approval from
the institutional review board (IRB). The Healthcare Cost and
Utilization Project (HCUP) provides detailed information about
the NIS database.
2.2. Study population
The included study population had to meet all of the following
inclusion criteria: 1) Age > 18 years, male or female; 2) patients
who underwent OMVR or TMVR for any indication of valvular
pathology; 3) sufficient clinical and demographic data available
for comparison. All patients age less that under 18 years of age,
or who underwent procedure than OMVR or TMVR were excluded.
The NIS database between duration October 2016 to September
2017 meeting procedure coding system (PCS) codes 02QG0Z and
02QG3Z for OMVR and TMVR, respectively were selected. The
PCS is a US cataloging system for procedural codes that track var-
ious open and transcutaneous interventions. The associated co-
morbidities and procedures were identified using the standardized
ICD-10 clinical modification (ICD-10-CM) and ICD-10-PCS.
2.3. Study outcomes
Baseline demographics, age, admitting diagnosis, hospital-level
characteristics, co-morbidities and concomitant procedures
between OMVR and TMVR were compared. Primary endpoints
were in-hospital mortality, and procedure and hospital cost in US
dollars ($). Secondary outcomes included mean length of hospital
stay and trends of procedure preference in terms of patient demo-
graphics and socioeconomic status.
2.4. Statistical analyses
The set discharge weight (DISCWT) provided by the NIS data-
base was applied to all variables to generate national estimates.
Categorical variables were assessed using the Pearson Chi-square
test and independent student’s t-tests were used for comparing
continuous variables between OMVR and TMVR groups. A multi-
variate analysis based on the ordinal logistic regression model
(OLR) was used to calculate odds ratios (aOR) adjusted for possible
covariates including age, race, sex, elective-non-elective, median
household income, admission type, length of stay, hospital bed
size, location/teaching status of the hospital and all baseline co-
morbidities. An alpha criterion of<0.05 was used as a cutoff for sta-
tistical significance. The analysis was performed using IBM SPSS
Statistics 22.0 (IBM Corp, Armonk, New York).
3. Results:
3.1. Baseline characteristics of the study population
A total of 19,580 patients who underwent MVR were identified.
Of these, 18,460 (94%) underwent OMVR and 1120 (6%) had TMVR.
The mean age of patients who underwent OMVR was 62.7 ± 15.3
years, significantly younger by 7.91 years ± 0.53 (p=<0.0001) com-
pared to TMVR (70.65 ± 13.17 years). Both cohorts consisted pre-
dominantly of Caucasian patients (73% OMVR versus 74.0%
TMVR), followed by African American (12% versus 11%), Hispanic
(7% versus 6%), and Asian (2% versus 2%). Baseline study demo-
graphics are shown in Table 1.
Table 1
Showing baseline demographics, co-morbidities, procedural complications.
Analyte TMVR OMVR
Demographics
Sample n (%) 1120 (6%) 18,460 (94%)
Age with range (years) 62.7 ± 15.3 70.65 ± 13.17 years
Males n (%) 330
(29.4%)
6920 (37.4%)
Females n (%) 520
(46.4%)
8375 (45.3%)
Caucasians 74% 73.00%
African Americans 11% 12%
Others race 8% 9%
Median household Income 1st Quartile:
1–43,999$ n (%)
245
(22.1%)
5020 (27.8%)
MHI 2nd Quartile: 44,000–55,999$ (n%) 315
(28.4%)
4735 (26.2%)
MHI 3rd Quartile: 56,000–73,999$ n (%) 260
(23.4%)
4320 (23.9%)
MHI 4th Quartile: >74,000$ n (%) 290
(26.1%)
3965 (22.0%)
New admission for sole purpose of
procedure n (%)
880
(78.6%)
15,700 (85.3%)
Transfer in from acute facility n (%) 210
(18.8%)
2345 (12.7%)
Transfer in from non-acute facility n (%) 30 (2.7%) 370 (2.0%)
No transfer out to other facility n (%) 825(73.7%) 12705(68.8%)
Transfer to acute care facility n (%) 5 (0.4%) 260 (1.4%)
Transfer out to non-acute care facility n
(%)
290
(25.9%)
5490 (29.7%)
Baseline Comorbidities n (%)
Hypertensive heart disease with heart
failure I110
25 (2.2%) 200 (1.1%)
Hypertension and chronic kidney disease
I-V
25 (2.2%) 290 (2.3%)
Rheumatic valvular disease 170 (14%) 6175 (33.4%)
Nonrheumatic valvular disease 275
(24.5%)
5980 (32.5%)
Procedural Characteristics
Number of Days from admission to
procedure
2.6 ± 4.5 3 ± 5
Length of hospital stay (days) 11.5 ± 10 14 ± 12.7
Total Cost ($) 318,882 38,341
Procedural Complications n (%)
Sepsis due to MSSA 10 (0.9%) 140 (0.8%)
Sepsis secondary to other strep and
staph
– 240 (1.3%)
Sepsis secondary to gram negative
infection and candida
– 200 (1.08%)
Acute and subacute infective
endocarditis
45 (4%) 900 (4.9%)
Atrial fibrillation 10 (0.8%) 85 (0.5%)
STEMI 20 (1.7%) 120(0.7%)
NSTEMI 50 (4.5%) 455 (2.5%)
Heart Failure 125 (1.1%)
Leakage/mechanical complication of
prosthesis
100 (8.9%) 315
Infection/thrombosis of prosthesis/other
complications
260
(23.2%)
1215
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3.2. Baseline comorbidities of the study population
The most common indications for valve replacement in the
OMVR and TMVR groups were nonrheumatic mitral valve insuffi-
ciency (29.2% vs. 20.5%) followed by rheumatic mitral stenosis
(5.1% vs. 5.4%). In addition to mitral valve involvement, OMVR
patients had associated additional valvular lesions, including rheu-
matic disorder of tricuspid valves (9.0%), rheumatic stenosis of aor-
tic valves (8.4%), and combined rheumatic disorders of aortic and
tricuspid valves (5.1%). Multiple valvular lesions justified the need
for open-heart surgery to have concomitant valvular replacements.
The baseline comorbidities, and indications are shown in table 1
and table 2 respectively.
In the TMVR cohort, 4.5% of patients had non-ST segment eleva-
tion myocardial infarction (NSTEMI), and 4.0% of patients had
acute or subacute infective endocarditis on presentation. Patients
in the TMVR group had significantly higher percentages of respira-
tory failure, heart failure, anemia, thrombocytopenia and car-
diomyopathy (p=<0.0001). (Fig. 1)
3.3. Hospital-based characteristics and Outcomes:
Average number of days from admission to the TMVR procedure
was 2.63 days, significantly lower compared to the OMVR group
(3.02 days, p = 0.015). The average in-hospital LOS was also mark-
edly lower by0.388days for the TMVRgroup compared to theOMVR
group (11.56 vs. 14.01 days, p=<0.0001). (Table 1; Table 3) Themean
cost for TMVR was $383,401, which was significantly higher com-
pared to OMVR ($318,882; p < 0.0001) (Table 3). The patients who
underwent TMVR were more likely to belong to a household with
an income in the highest 4th quartile (26.1%vs. 22.0%) and less likely
to be in the lowest 1st quartile (22.1% vs. 27.8%).
Approximately 7% of TMVR patients, and 9% of OMVR patients
were admitted on the weekend. Sixty three percent of TMVR
patients and 64% of OMVR patients underwent an elective proce-
dure. The adjusted odds for weekend admissions (OR 0.814, 95%
CI 0.622–1.065, p = 0.15) and elective procedure (OR 1.005, 95%
CI 0.870–1.161, p = 0.973) were not significantly different between
groups. (Table 4)
In-hospital mortality was significantly higher for the TMVR
group at 13.4%, as compared to the OMVR group at 5.3%
(p = 0.013). However, the adjusted odds of in-hospital mortality
taking into co-morbidities showed no significant difference
between the two groups (OR 1.2, 0.93–1.68, p = 0.15). (Table 4)
The survival analysis of TMVR and OMVR is shown in Kaplan-
Meier curve in Fig. 2. The subgroup analysis showed similar mor-
tality across both genders in OMVR. The mortality review among
subgroups were more prevalent in OMVR with organ failure, and
the most common complication were respiratory failure, hepatic
failure, acute kidney injury and heart failure. Further subgroup dif-
ference of mortality in terms of race, gender, and complications are
shown in table 5.
Table 2
Showing indications of OMVR and TMVR with sample frequency and percentages.
ICD-10 CODE and indication for the procedure OMVR % TMVR %
Nonrheumatic mitral (valve) insufficiency (I340) 5385 29.20% 230 20.50%
Rheumatic disorders of both mitral and tricuspid valves (I081) 1660 9.00% 25 2.20%
Rheumatic disorders of both mitral and aortic valves (I080) 1545 8.40% 25 2.20%
Rheumatic mitral stenosis with insufficiency (I052) 950 5.10% 60 5.40%
Rheumatic mitral stenosis (I050) 675 3.70% 25 2.20%
Nonrheumatic mitral (valve) insufficiency (I340) 5385 29.20% 230 20.50%
Stenosis of other cardiac prosthetic devices, implants and grafts, initial encounter (T82857A) 570 3.10% 195 17.40%
Rheumatic mitral stenosis with insufficiency (I052) 950 5.10% 60 5.40%
Non-ST elevation myocardial infarction (NSTEMI) (I214) 455 2.50% 50 4.50%
Acute and subacute infective endocarditis (I330) 900 4.90% 45 4%
Fig. 1. Baseline comorbidities of patients across TMVR and OMVR. p-values shown on top of each bar chart represent statistically significant distribution among both groups
for all comorbidities.
W. Ullah et al. / IJC Heart & Vasculature 28 (2020) 100540 3
4. Discussion:
The main findings of this study are: (1) Patients with TMVR had
a higher socioeconomic status and were older compared to OMVR.
(2) TMVR patients had a lower in-hospital stay and had a shorter
admission to procedure time. (3) The unadjusted in-hospital mor-
tality odds were higher for TMVR patients. However, there was no
significant difference between the two groups when the odds of
mortality were adjusted based on co-morbidities. (4) Patients
undergoing TMVR did not differ significantly from OMVR in terms
of admission day (weekday vs. weekend) and procedure type
(emergent vs. elective).
TMVR offers a less invasive approach and quicker recovery com-
pared to OMVR for eligible patients with mitral regurgitation [3]. A
team of specialists is involved in determining the eligibility for
TMVR and requires an elaborate screening protocol [4]. Patients
with isolated mitral valve disease would benefit the most from
TMVR, while OMVR is preferred in patients with multiple valvular
lesions or having a concomitant coronary artery disease [3]. Addi-
tionally, the complexity of mitral anatomy, device-related factors,
Table 3
Clinical outcomes of continuous variables between patients undergoing OMVR vs. TMVR.
Characteristic OMVR TMVR Mean difference SE T-test p-value
Total charges (US$) 318,882 383,401 64518 8254 7.8 <0.0001
Admission to procedure (days) 3.02 2.63 0.397 0.163 2.4 0.015
Length of stay (days) 14.01 11.56 2.448 0.388 6.3 <0.0001
Abbreviations: OMVR: Open mitral valve replacement; TMVR: Transcatheter mitral valve replacement.
Table 4
Clinical outcomes of categorical variables between patients undergoing OMVR vs. TMVR.
Characteristics OMVR TMVR Chi-Square P-value
Mortality Rate % (deaths/total procedure) 5.3% (985/18455) 13.4% 150/112 125.44 0.00
Elective Vs non-elective procedure 11485/18370. 62.50% 575/1120 51.30% 55.947 0.00
Abbreviations: OMVR: Open mitral valve replacement; TMVR: Transcatheter mitral valve replacement.
Fig. 2. Kaplan Meir Curve showing in-hospital mortality of OMVR and TMVR.
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physician’s discretion and expertise also plays a role in decision
making. Being a relatively novel approach with limited evidence,
reported experience on TMVR outcome is limited; consequently,
even skilled physicians may opt to perform OMVR on patients with
complex mitral lesions [3,4]. The commercially available device
design (MitraClip) may limit application in the comorbid, dynamic
environment of the mitral annulus. To size and position these
devices on asymmetrical and saddle-shaped mitral annulus could
be challenging [7]. Similarly, calcified and rheumatic mitral disease
repaired by TMVR may produce suboptimal results as they may
pose an increased risk of left ventricular outflow tract obstruction,
late device detachment, and paravalvular leakage [8]. These poten-
tial complications are weighed against the surgical risk of OMVR to
decide about the appropriate intervention.
This study showed that patients undergoing TMVR were rela-
tively older by a mean age of about eight years compared to
patients undergoing OMVR. These findings were consistent with
the results of previous studies (Vassileva et al., and Del Val
et al.), where the mean age of patients undergoing TMVR was
approximately 75 years compared to 50 years for patients under-
going OMVR [9,10]. TMVR, thus, presents itself as a safer alterna-
tive in patients with advanced age where frailty, multiple co-
morbidities and stress intolerance renders them at high risk for
open surgery [11].
This study also found that TMVR was more frequently per-
formed in patients with higher socioeconomic status compared
to patients undergoing OMVR. There was no statistically significant
difference demonstrated between patients admitted on weekdays
vs. weekends or patients undergoing emergent vs. elective proce-
dure. TMVR patients had a shorter overall in-hospital length of
stay, yet the mean cost for overall TMVR related hospitalization
was significantly higher compared to OMVR. Continued advance-
ment in procedural technique and increasing availability of the
TMVR devices will reduce its cost in the future. A patient-level eco-
nomic analysis in the context of its long-term benefits is required
to determine its financial implications.
The adjusted mortality odds in patients undergoing TMVR was
not significantly different from patients undergoing OMVR. On
the contrary, in a multicenter, retrospective study by Guerrero
et al., the 30-day and 1-year all-cause mortality associated with
TMVR was 25% and 53.7%, respectively [12]. Elbadawi et al. also
reported about 2% overall in-hospital mortality in patients with
TMVR compared to 6% for patients undergoing OMVR [6]. This
mortality rate was found to be directly correlated with the degree
of mitral regurgitation and left ventricular dysfunction [13,14]. Our
unadjusted analysis showed a significantly higher in-hospital mor-
tality for patients undergoing TMVR compared to the OMVR (13.4%
vs. 5.3%, respectively). When adjusted for the relatively sicker pop-
ulations in the TMVR group, there was no significant difference in
the mortality odds of the two groups. This indicates that TMVR has
potentially equal efficacy as OMVR and could be a viable option for
patients with multiple comorbidities.
5. Limitations:
Due to the retrospective cross-sectional and nonrandomized
nature of the data, this study is subject to the selection bias, con-
founding bias, and also failure to associate definitive causation.
Furthermore, due to cross sectional nature of the study, the time
wise long-term graphical presentation of Kaplan Meier curve was
not possible. The reported findings merely represent an association
between different variables and inferences drawn about the inci-
dence of the outcomes could be misleading.
6. Conclusion:
TMVR appears to be an attractive alternative to OMVR due to a
significantly lower hospital stay, admission to procedure time and
an identical risk of mortality. The associated cost with TMVR was
high and more studies are needed to determine the cost-benefit
analysis.
Disclosures: none
Appendix A. Supplementary data
Supplementary data to this article can be found online at
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